newsfilter
← Latest News
GlobeNewswire·

Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026

  • Lexeo Therapeutics will report third quarter 2026 financial results & provide a business update on the HEROIC-PKP2 Phase I/II clinical trial for LX2020 on Monday, November 16, 2026.
  • A webcast of the event is scheduled for 8:00 AM ET on November 16, 2026, with a replay available via the company's Investor Relations website.
  • LX2020 is an AAVrh10-based gene therapy candidate designed to deliver a functional PKP2 gene to cardiomyocytes to treat plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM).
  • PKP2 gene mutations cause approximately 50% of ACM cases, affecting an estimated 60,000 people in the United States.
  • The HEROIC-PKP2 trial is a single-arm, open-label, multi-center study (NCT06109181) evaluating the safety & efficacy of LX2020.
  • LX2020 holds FDA designations as a Regenerative Medicine Advanced Therapy, Orphan Drug, & Fast Track candidate.
  • Lexeo Therapeutics is advancing a portfolio of gene therapies including LX2006 for Friedreich ataxia (FA) & LX2020 for PKP2-ACM.
  • The press release includes standard forward-looking statements cautioning that actual results may differ from expectations due to risks such as clinical trial outcomes, regulatory approvals, & capital resources.
Company
Lexeo Therapeutics
Keywords
Nasdaq:LXEO, Lexeo Therapeutics